trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['destiny,breast,2', 'breast', 'pantumor', 'dance', 'destiny,breast,3', 't-dxd', 'basket trial']
at the #asco23 #developmentaltherapeutics orals discusses the first 3 abstracts, noting for the destiny-pantumor02 basket trial of t-dxd the importance of her2 testing and issues with concordance between local and central assessment in non-breast tumor types 
Executive Editor of Cancer Discovery @CD_AACR, published by @AACR. @BBS_Harvard/@DanaFarber alum. Native New Yorker. Views/likes/RTs are my own. She/her